http://www.wallstreetreporter.com Profitable investing ideas Thu, 09 Feb 2012 18:44:44 +0000 en hourly 1 http://wordpress.org/?v=3.1 © http://www.wallstreetreporter.com/?feed=podcast jmarks@wallstreetreporter.com () jmarks@wallstreetreporter.com() 1440 Just another WordPress weblog jmarks@wallstreetreporter.com No no http://www.wallstreetreporter.com/wp-content/plugins/podpress/images/powered_by_podpress.jpg http://www.wallstreetreporter.com 144 144 http://www.wallstreetreporter.com/2010/06/neostem-achieves-new-milestone-as-company-joins-russell-3000-index/ http://www.wallstreetreporter.com/2010/06/neostem-achieves-new-milestone-as-company-joins-russell-3000-index/#comments Mon, 28 Jun 2010 16:08:09 +0000 admin http://www.wallstreetreporter.com/?p=4493 http://www.wallstreetreporter.com/2010/06/neostem-achieves-new-milestone-as-company-joins-russell-3000-index/feed/ 0 http://www.wallstreetreporter.com/2010/06/neostem-provides-business-update/ http://www.wallstreetreporter.com/2010/06/neostem-provides-business-update/#comments Tue, 08 Jun 2010 14:56:41 +0000 admin http://www.wallstreetreporter.com/?p=4277 http://www.wallstreetreporter.com/2010/06/neostem-provides-business-update/feed/ 0 http://www.wallstreetreporter.com/2010/05/neostem-inc-amex-nbs-ceo-interview/ http://www.wallstreetreporter.com/2010/05/neostem-inc-amex-nbs-ceo-interview/#comments Fri, 28 May 2010 16:36:57 +0000 admin http://www.wallstreetreporter.com/?p=3956 http://www.wallstreetreporter.com/2010/05/neostem-inc-amex-nbs-ceo-interview/feed/ 0 12:25 NeoStem, Inc (AMEX: NBS) Dr. Robin Smith, Chairman CEO CORPORATE PROFILE: NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and ... NeoStem, Inc (AMEX: NBS) Dr. Robin Smith, Chairman CEO CORPORATE PROFILE: NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com . TRANSCRIPT: Juan Costello: Good day from Wall Street. This is Juan Costello, Senior Analyst with the Wall Street Reporter. Joining us today is Dr. Robin Smith, CEO and Chairman of NeoStem Incorporated. The company trades on AMEX and their ticker symbol is NBS. They're an international biopharmaceutical company, which helps individuals to collect and store their own adult stem cells for future medical use and usually leveraging their VSEL technology. Thanks for joining us today, Dr. Smith. Dr. Robin Smith: Great to be back. Juan Costello: Great. It's always good to have you on. Starting off, for some of our investor audience thatrsquo;s new to the NeoStem story, talk to us a little bit more about your technology? Dr. Robin Smith: Sure. It's been a transformational year for us and we have expanded into China. As you said, we're an international company, and we began by realizing that our collection and storage side of our business in United States was guided by therapies. People want to have their stem cells treatments to store their stem cells today for future use. So, we expanded our business into China and basically licensed a few technologies for stem cell applications that we can start treating patients and generating revenue in orthopedics, cosmetics and anti-aging. So, that's an exciting expansion of our stem cell side of the business while we develop our VSEL technology, which is very small embryonic-like stem cell. You and I have embryonic stem cells in our body. So, you don't have the controversial ethical issues of destroying embryonic stem cells that are in you that we can harvest and purify and freeze for future use, and we're focusing on taking these and discovering application for different therapies. Juan Costello: How has NeoStem changed from our last interview, which was about a year ago? Dr. Robin Smith: I think one of the biggest milestones we've had is the end of October -- October 30th 2009, we purchased a majority interest in a therapeutic pharmaceutical company in China doing over $60 million in revenue there. That division has over $12 million in profits, over a 100 drugs are produced, distributed into all provinces in China. They manufacture seven out of the top 20 China pharmaceutical antibiotics that are used. Healthcare reform in China is tremendous. It's a $124 billion a year, growing at 24% for antibiotics and it's projected to triple by 2013. So, it's just a wonderful market and this is a fantastic pharmaceutical company that's well run. Theyrsquo;ve been capacity constraint and in the middle of a relocation that will allow doubling their capacity. So, to be in an industry where there is demand and then you can increase your supply is just terrific, and we can bring new drugs and new applications to them through the distribution model that's been built over 60 years. Juan Costello: Talk a little bit about some of your subsidiaries such as Suzhou Erye and what we can expect from them? Dr. Robin Smith: So, that's the company I just told y... CEO,Interview,,Spotlight,Stocks jmarks@wallstreetreporter.com no No http://www.wallstreetreporter.com/2010/02/neostem-chinese-subsidiary-receives-ok-from-china-sfda-to-manufacture-penicilin/ http://www.wallstreetreporter.com/2010/02/neostem-chinese-subsidiary-receives-ok-from-china-sfda-to-manufacture-penicilin/#comments Mon, 01 Feb 2010 14:20:44 +0000 admin http://www.wallstreetreporter.com/?p=3351 http://www.wallstreetreporter.com/2010/02/neostem-chinese-subsidiary-receives-ok-from-china-sfda-to-manufacture-penicilin/feed/ 0